SCHEMBL5560286

SCHEMBL5560286

COc1cc2c(CC(N)=O)c(C)n(C(=O)c3ccc(OC(F)F)cc3)c2cc1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 7/20 0.57
PLA2G2A P14555 1/20 0.56
AKR1C3 P42330 9/20 0.51
AKR1C2 P52895 6/20 0.51
PTGS1 P23219 2/20 0.50
ABCB1 P08183 2/20 0.46
LMNA P02545 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
HIF1A Q16665 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
PTGES O14684 1/20 0.46
ABCC3 O15438 1/20 0.46
ABCC4 O15439 1/20 0.46
ABCB11 O95342 1/20 0.46
MT-CO2 P00403 1/20 0.46
ALB P02768 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5440977 0.91 AKR1C3 (0.62) PTGS2PLA2G2AAKR1C3AKR1C2PTGS1
SCHEMBL5554235 0.90 PTGS2 (0.64) PTGS2PLA2G2AAKR1C3AKR1C2PTGS1
SCHEMBL5558752 0.89 PTGS2 (0.58) PTGS2AKR1C3AKR1C2PTGS1NPSR1
SCHEMBL5554258 0.89 PTGS2 (0.54) PTGS2PLA2G2AAKR1C3AKR1C2PTGS1
SCHEMBL6425552 0.88 PTGS2 (0.58) PTGS2PLA2G2AAKR1C3AKR1C2PTGS1
SCHEMBL6425259 0.88 AKR1C3 (0.59) PTGS2PLA2G2AAKR1C3AKR1C2PTGS1
SCHEMBL5559389 0.88 PTGS2 (0.51) PTGS2
SCHEMBL6423827 0.88 PTGS2 (0.58) PTGS2PLA2G2AAKR1C3AKR1C2PTGS1
SCHEMBL5558744 0.87 PTGS2 (0.51) PTGS2AKR1C3AKR1C2PTGS1
SCHEMBL5553810 0.87 PTGS2 (0.62) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1643961-A4 COX-2 AND FAAH INHIBITORS MICROBIA INC (US) 2007-09-12 EP disclosed
WO-2006050120-A2 SYNTHESIS OF COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2006-05-11 WO disclosed
EP-1643961-A2 COX-2 AND FAAH INHIBITORS Microbia, Inc. (US) 2006-04-12 EP disclosed
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed
US-20050032747-A1 COX-2 and FAAH inhibitors POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2005-02-10 US disclosed
WO-2005002525-A2 COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032747-A1 COX-2 and FAAH inhibitors FAAH2, FAAH, PTGS2 PTGS2 3/4885PLA2G2A 54/4885AKR1C3 585/4885
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 PTGS2 4/4885PLA2G2A 62/4885AKR1C3 577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.